NewLimit

“NewLimit ($435M at $3.1B from Founders Fund) — biotechnology company focused on epigenetic reprogramming for aging.”

“Founders Fund leading NewLimit's $435M Series C is a signal worth tracking separately from the round size — it indicates Peter Thiel's firm is doubling down on biological age-reversal as a core thesis.”

“NewLimit, a biotechnology company, has closed a $435M Series C funding led by Founders Fund.”